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cr-Allenyl putrescine (5,6-heptadiene-1,4-diamine) was designed as a new potential enzyme-activated irre- 
versible inhibitor of ornithine decarboxylase (ODC). This compound, and more specifically its (R)-enan- 
tiomer, produced time-dependent inhibitions of E. coli and rat liver ODC. The inhibitions exhibit saturation 
kinetics and were not relieved by prolonged dialysis of the inactivated enzyme. Selective inactivation of the 
two types of ODC by the (I?)-enantiomer is in agreement with the stereochemistry reported for ornithine 
decarboxylation by the enzyme. Kinetic constants of E. coli ODC inactivation by a-(R)-allenyl putrescine 
compare favorably with other irreversible inhibitors of this enzyme. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Considerable progress in the knowledge of the 
functional role of polyamines was achieved thanks 
to the availability of specific inhibitors of ornithine 
decarboxylase (EC 4.1.1.17, ODC), the enzyme 
responsible for the biosynthesis of putrescine [1,2]. 
Among these inhibitors, enzyme-activated irre- 
versible inhibitors (also referred to as suicide sub- 
strates) [3,4] have proven to be particularly 
valuable. Such ODC inhibitors were cu-halomethyl, 
a-vinyl and cu-ethynyl analogues of ornithine and 
putrescine [5,8]. Mechanistic considerations led to 
suggest that the cu-allenyl analogues were also 
potential enzyme-activated irreversible inhibitors 
of ODC [9]. We recently described the synthesis of 
a-allenyl putrescine (5,6-heptadiene-1,4-diamine) 
and of its (R)- and (S)-enantiomers [9]. Here, we 
report the effects of these compounds on bacterial 
and mammalian ODC, in vitro. 
2.1. Chemicals 
DL-[l-14C]Ornithine (58 Ci/mol) was purchased 
from the Radiochemical Centre, Amersham. All 
other chemical products were of the purest grade 
commercially available. 
2.2. Enzymes 
Biosynthetic E. coli ODC was prepared as fol- 
lowing: E. coli (PR7 strain), a gift from Dr J.E. 
Davies, was grown according to [lo]. Cells were 
washed with 30 mM phosphate buffer (pH 7.8) and 
resuspended in 30mM Tris-HCl buffer (pH 8.2) 
containing pyridoxal phosphate (0. I mM), dithio- 
threitol(5 mM) and EDTA (0.1 mM). After sonica- 
tion, the cell debris were removed by centrifugation 
at 20000 x g for 30 min. The 105 000 x g super- 
natant, dialysed against the buffer used for homo- 
genisation, was used for enzyme activity measure- 
ments. Specific activity of this preparation was 
16 nmol COz/min per mg protein. 
Mammalian ODC was prepared from livers of 
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rats which had been injected with thioacetamide 
(150 mg/kg body wt) 18 h before sacrifice, and was 
purified about lo-fold from the homogenate by 
acid treatment at pH 4.6 as in [ 111. Specific activity 
of this preparation was 0.2 nmol COz/min per mg 
protein. 
2.3. Assays of time-dependent inhibition of ODC 
For a typical experiment, 320~1 of stock solution 
of enzyme were mixed at time 0 with 80~1 of a 
solution of a-allenyl putrescine in water and incu- 
bated at 37°C. At various times, 25~1 aliquots 
were transferred into a 0.975 ml assay medium in 
a closed vessel in which a filter paper moistened 
with 50~1 of hyamine hydroxide (1 M) was fitted. 
The assay medium for the E. coli enzyme con- 
tained Tris-HCI (30 mM, pH 8.2), pyridoxal phos- 
phate (0.01 mM), dithrothreitol (5 mM), L-orni- 
thine (5 mM) and DL-[l-‘4C]ornithine (1.25,&i). 
For the rat liver enzyme, the assay medium con- 
tained sodium phosphate (30 mM, pH 7.1), pyri- 
doxal phosphate (0.1 mM), dithiothreitol (5 mM), 
L-ornithine (0.09 mM) and DL-[l-‘4C]ornithine 
(1.25 ,uCi). The reaction was allowed to proceed for 
60min at 37°C and was then terminated by the 
addition of 0.5 ml of 40% trichloroacetic acid. 
After an additional 30 min, the 14C02 absorbed on 
the filter paper was counted in a standard scintilla- 
tion cocktail. 
3. RESULTS 
Incubation of the E. coli ODC preparation with 
a-allenyl putrescine resulted in a time-dependent 
loss of enzyme activity which followed pseudo 
first-order kinetics for approximately two half- 
lives. Over longer time periods, the semilogarith- 
mic plot deviated from linearity (fig.1). Loss of 
activity was related to the concentration of inhibi- 
tor. By plotting the time of half inactivation (tm) 
as a function of the reciprocal of the inhibitor con- 
centration (l/Z) according to [ 121, a straight line 
was obtained (fig-l). This line does not pass 
through the origin but intercepts the positive y- 
axis, demonstrating a saturation effect which in- 
volves the enzyme’s active site in the inhibitory 
process. Kinetic constants for the time-dependent 
inhibition (Kr, the apparent dissociation constant 
and 7r12 the time of half inactivation at infinite 
concentration of inhibitor) can be extrapolated 
from fig. 1 and are given in table 1. The presence 
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Fig. 1. Time- and concentration-dependent inhibition of 
E. coli ODC in vitro. ODC was incubated at 37°C with 
Tris-HCl buffer (30 mM, pH 8.2), dithiothreitol (5 
mM), pyridoxal phosphate (0.1 mM), EDTA (0.1 mM) 
and various concentrations of cu-allenyl putrescine: (0) 
control; (0) 10gm; (A) 17pM; (A) 25,uM; (*) SO/cM; 
(0) 1OOpM). In the lower part of the figure, the times of 
half inactivation (tr,z) are plotted against the reciprocal 
of the inhibitor concentration. 
of dithiothreitol (5 mM) in the preincubation 
medium and the absence of a lag-time before the 
onset of inhibition rule out the possibility of inac- 
tivation via affinity labeling mode by a diffusible 
alkylating species [ 131. Incubation with a-allenyl 
putrescine (0.1 mM) resulted in 95% inactivation 
of E. coli ODC after 30min. Prolonged (24 h) 
dialysis of the inactivated ODC against a buffer 
solution containing Tris-HCl (30 mM, pH 8.2), 
pyridoxal phosphate (0.1 mM) and dithiothreitol 
(5 mM) (conditions under which the native enzyme 
is stable) did not lead to regeneration of enzyme 
activity, thus demonstrating the irreversibility of 
the inhibition. 
Further experiments with the two optical iso- 
mers of a-allenyl putrescine showed that the in- 
hibitory activity resides only in the (Z?)-enantiomer 
(fig.2). This enantiomer has a KI of 140gM, i.e., 
approximately half that of the racemic mixture. 
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Table 1 
Kinetic constants of ODC inactivation by a-allenyl putrescine and its enantiomers 
cu-(RS)-allenyl putrescine 
cY-(R)-allenyl putrescine 
a-Wallenyl putrescine 
E. coli ODC 
KI (PM) n/2 (min) 
300 1.4 
140 2 
No time-dependent 
inhibition at 2 mMa 
rat liver ODC 
KI (PM) n/2 bin) 
160 8 
70 10 
3400 25 
acu-(S)-allenyl putrescine was found to be a weak competitive inhibition of E. coli ODC (KI = 1.5 mM) 
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Fig.2. Time-dependent inhibition of E. cofi ODC cy- 
allenyl putrescine enantiomers. ODC was incubated at 
37°C under conditions described in fig.1 with (0) 
0.03 mM cu-(I?)-allenyl putrescine, or (0) 3 mM G+(S)- 
allenyl putrescine. 
cu-Allenyl putrescine and its enantiomers were 
also tested as time-dependent inhibitors of mam- 
malian ODC. Results were qualitatively similar to 
those obtained with the bacterial enzyme. The 
main difference is that the (S)-enantiomer, at milli- 
molar concentrations, inactivates rat liver ODC in 
a time-dependent manner (see table 1). 
4. DISCUSSION 
Our results represent he first example of an a- 
allenyl derivative of an amine as being an enzyme- 
activated irreversible inhibitor of a pyridoxal 
phosphate-dependent decarboxylase. Other allenyl 
amines were reported to be irreversible inhibitors 
of the flavin-enzyme monoamine oxidase (EC 
1.4.3.4.) [14,15]. a-Allenyl GABA was claimed to 
be an irreversible inhibitor of GABA transaminase 
(EC 2.6.1.19) but results were not shown [16]. 
Here, we show the (R)-enantiomer of Lu-allenyl 
putrescine is the active optical isomer in the inhibi- 
tion of both bacterial and mammalian ODC. This 
is in agreement with a previous finding that the 
(R)-enantiomer of y-ethynyl putrescine inactivates 
ODC [17,18] and with the stereochemistry of bac- 
terial ODC which decarboxylates L-ornithine with 
retention of configuration [ 191. Inactivation of 
mammalian ODC by high concentrations of cu-(S)- 
allenyl putrescine represents a further example of 
the lack of stringent stereospecificity in the inacti- 
vation of various pyridoxal phosphate-dependent 
enzymes by suicide substrates discussed recently 
P81. 
cY-Allenyl putrescine and its (R)-enantiomer do 
not compare favorably with other enzyme-acti- 
vated irreversible inhibitors of mammalian ODC 
[8]. However, cY-(R)-allenyl putrescine inactivates 
E. coli ODC at the same rate as a-monofluoro- 
methyl putrescine which, so far, was the most 
potent inhibitor of this enzyme [20]. Inhibitors of 
polyamine biosynthesis have been used success- 
fully to block bacterial growth [2,21,22]. In this 
respect, a-(Z?)-allenyl putrescine represents a pro- 
mising alternative. 
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